Table 5.
Prognostic Factors
| Serum AFP Levels (n = 537) | |
| Log 10 ng/dL, mean (SD, min-max) | 2.0 (1.3, 0-4.8) |
| Category, n (%) | |
| ≤20 ng/dL | 204 (38.0) |
| 21-400 ng/dL | 160 (29.8) |
| 401-1000 ng/dL | 53 (9.9) |
| >1000 ng/dL | 120 (22.3) |
| ECOG performance status (n = 536), n (%) | |
| 0 | 229 (42.7) |
| 1 | 215 (40.1) |
| 2 | 52 (9.7) |
| 3 | 30 (5.6) |
| 4 | 10 (1.9) |
| 5 | 0 |
| Child–Pugh Scoring (n = 511), n (%) | |
| Class A | 287 (56.2) |
| Class B | 171 (33.5) |
| Class C | 53 (10.5) |
| BCLC stage (n = 517), n (%) | |
| 0 (very early stage) | 73 (14.1) |
| A (early stage) | 150 (29.0) |
| B (intermediate stage) | 124 (24.0) |
| C (advanced stage) | 137 (26.5) |
| D (terminal stage) | 33 (6.4) |
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group.